WO1998021333A3 - Nucleic acid encoding schwannomin-binding-proteins and products related thereto - Google Patents

Nucleic acid encoding schwannomin-binding-proteins and products related thereto Download PDF

Info

Publication number
WO1998021333A3
WO1998021333A3 PCT/US1997/021005 US9721005W WO9821333A3 WO 1998021333 A3 WO1998021333 A3 WO 1998021333A3 US 9721005 W US9721005 W US 9721005W WO 9821333 A3 WO9821333 A3 WO 9821333A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
schwannomin
binding
nucleic acid
acid encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/021005
Other languages
French (fr)
Other versions
WO1998021333A2 (en
Inventor
Stefan M Pulst
Daniel R Scoles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Priority to AU71802/98A priority Critical patent/AU7180298A/en
Priority to JP52290098A priority patent/JP2001504341A/en
Priority to CA002270875A priority patent/CA2270875A1/en
Priority to EP97949469A priority patent/EP0942977A2/en
Publication of WO1998021333A2 publication Critical patent/WO1998021333A2/en
Publication of WO1998021333A3 publication Critical patent/WO1998021333A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

In accordance with the present invention, there are provided novel Schwannomin-Binding-Proteins (SBPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SBPs can be employed in a variety of ways, for example, for the production of anti-SBP antibodies thereto, in therapeutic compositions and methods employing such proteins and/or antibodies. Also provided are transgenic non-human mammals that express the invention protein.
PCT/US1997/021005 1996-11-15 1997-11-14 Nucleic acid encoding schwannomin-binding-proteins and products related thereto Ceased WO1998021333A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU71802/98A AU7180298A (en) 1996-11-15 1997-11-14 Nucleic acid encoding schwannominbinding-proteins and products related th ereto
JP52290098A JP2001504341A (en) 1996-11-15 1997-11-14 Nucleic acids encoding schwannomin binding proteins and related products
CA002270875A CA2270875A1 (en) 1996-11-15 1997-11-14 Nucleic acid encoding schwannomin-binding-proteins and products related thereto
EP97949469A EP0942977A2 (en) 1996-11-15 1997-11-14 Nucleic acid encoding schwannomin-binding-proteins and products related thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3098796P 1996-11-15 1996-11-15
US60/030,987 1996-11-15

Publications (2)

Publication Number Publication Date
WO1998021333A2 WO1998021333A2 (en) 1998-05-22
WO1998021333A3 true WO1998021333A3 (en) 1999-01-14

Family

ID=21857044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/021005 Ceased WO1998021333A2 (en) 1996-11-15 1997-11-14 Nucleic acid encoding schwannomin-binding-proteins and products related thereto

Country Status (6)

Country Link
US (3) US6376174B1 (en)
EP (1) EP0942977A2 (en)
JP (1) JP2001504341A (en)
AU (1) AU7180298A (en)
CA (1) CA2270875A1 (en)
WO (1) WO1998021333A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6440798A (en) * 1997-02-26 1998-09-18 Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulation of vesicular release
GB9819914D0 (en) * 1998-09-11 1998-11-04 European Molecular Biology Lab Embl Genetic suppression therapy
US6610306B2 (en) 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
US7803906B2 (en) 2002-03-22 2010-09-28 Gene Signal International Sa Composition comprising an angiogenesis related protein
FR2837391B1 (en) * 2002-03-22 2007-04-20 Gene Signal REGULATORY GENES OF ANGIOGENESIS, PHARMACEUTICAL PREPARATIONS CONTAINING SAME AND APPLICATIONS THEREOF
WO2006015079A2 (en) * 2004-07-27 2006-02-09 Yale University Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
ES2674710T3 (en) 2007-05-16 2018-07-03 Gene Signal International Sa Drug, medication, antitumor composition and use thereof
EP4205288A4 (en) 2020-08-28 2024-10-30 ISCO International, LLC METHOD AND SYSTEM FOR MITIGATING NEAR-FIELD INTERFERENCE
US11476585B1 (en) 2022-03-31 2022-10-18 Isco International, Llc Polarization shifting devices and systems for interference mitigation
US11476574B1 (en) 2022-03-31 2022-10-18 Isco International, Llc Method and system for driving polarization shifting to mitigate interference
US11502404B1 (en) 2022-03-31 2022-11-15 Isco International, Llc Method and system for detecting interference and controlling polarization shifting to mitigate the interference
US11509071B1 (en) 2022-05-26 2022-11-22 Isco International, Llc Multi-band polarization rotation for interference mitigation
US11515652B1 (en) 2022-05-26 2022-11-29 Isco International, Llc Dual shifter devices and systems for polarization rotation to mitigate interference
US11509072B1 (en) 2022-05-26 2022-11-22 Isco International, Llc Radio frequency (RF) polarization rotation devices and systems for interference mitigation
US11990976B2 (en) 2022-10-17 2024-05-21 Isco International, Llc Method and system for polarization adaptation to reduce propagation loss for a multiple-input-multiple-output (MIMO) antenna
US11956058B1 (en) 2022-10-17 2024-04-09 Isco International, Llc Method and system for mobile device signal to interference plus noise ratio (SINR) improvement via polarization adjusting/optimization
US11949489B1 (en) 2022-10-17 2024-04-02 Isco International, Llc Method and system for improving multiple-input-multiple-output (MIMO) beam isolation via alternating polarization
US11985692B2 (en) 2022-10-17 2024-05-14 Isco International, Llc Method and system for antenna integrated radio (AIR) downlink and uplink beam polarization adaptation
US12301298B1 (en) 2023-12-29 2025-05-13 Isco International, Llc Methods and systems for locating interference sources via angle of arrival (AoA)
US12348285B1 (en) 2023-12-29 2025-07-01 Isco International, Llc Methods and systems for detecting, measuring, and/or locating passive intermodulation (PIM) sources via beamforming
US12219522B1 (en) 2023-12-29 2025-02-04 Isco International, Llc Methods and systems for estimating the shape of an object generating passive intermodulation (PIM) interference
US12301315B1 (en) 2023-12-29 2025-05-13 Isco International, Llc Methods and systems for detecting, measuring, and/or locating passive intermodulation sources via downlink (DL) signal injection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASANO K. ET AL.: "Conservation and diversity of eukariotic translation initiation factor elF3", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 2, 10 January 1997 (1997-01-10), MD US, pages 1101 - 1109, XP002076568 *
PAUL M.A. ET AL.: "characterization of fodrin interaction with the NF2 tumor suppressor gene product schwannomin (merlin) and varying strenghts of protein binding that correlate with NF2 patient phenotypes", NEUROLOGY, vol. 48, no. 3 (suppl.2), April 1997 (1997-04-01), XP002063404 *
SCOLES D.R. ET AL.: "Identification and characterization of interaction between the NF2 geneproduct Schwannomin and beta-II-spectrin", MOLECULAR BIOLOGY OF THE CELL, vol. 7 (supplement), December 1996 (1996-12-01), XP002063405 *
SCOLES D.R. ET AL.: "The neurofibromatosis 2 gene product schwannomin interacts with beta-II-spectrin", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 59, no. 4(suppl.), 2 November 1996 (1996-11-02), XP002063403 *
TAKESHIMA H. ET AL.: "Detection of cellular proteins taht interact with the NF2 tumor suppressor gene", ONCOGENE, vol. 9, no. 8, August 1994 (1994-08-01), GB, pages 2135 - 2144, XP002063402 *

Also Published As

Publication number Publication date
AU7180298A (en) 1998-06-03
CA2270875A1 (en) 1998-05-22
US20060199195A1 (en) 2006-09-07
US6376174B1 (en) 2002-04-23
JP2001504341A (en) 2001-04-03
EP0942977A2 (en) 1999-09-22
WO1998021333A2 (en) 1998-05-22
US6960650B2 (en) 2005-11-01
US20020168672A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
WO2000001815A3 (en) Neurotrophic factors
WO2002032925A3 (en) Protein scaffolds for antibody mimics and other binding proteins
WO1994018316A3 (en) Apolipoprotein b mrna editing protein compositions and methods
CA2293819A1 (en) A method for in vitro molecular evolution of protein function
EP1137941A4 (en) Protein scaffolds for antibody mimics and other binding proteins
ZA988392B (en) Tie ligand homologues.
AU2827895A (en) Purified polyporus laccases and nucleic acids encoding same
PT1015585E (en) HOMES OF TIE LIGANDOS
AU2656595A (en) Purified myceliophthora laccases and nucleic acids encoding same
WO1998021343A8 (en) Genes encoding telomerase proteins
GR3019849T3 (en) Acute pancreatitis associated protein and means for the diagnosis of acute pancreatitis
WO2001068824A3 (en) Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
WO1995006735A3 (en) Nucleotide sequences for novel protein tyrosine phosphatases
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
DE60122562D1 (en) NUCLEIC ACIDS CODED FOR STICHODACTYLIDAE CHROMOPROTEINS
DE69634077D1 (en) HAEMOPHILUS ADHESION PROTEINS
WO2000012710A8 (en) Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
HK1040420A1 (en) Metabolic selection methods
WO1999022005A3 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
EP0352228A3 (en) Novel proteins
NZ294019A (en) Proteins associated with the hippocampus; dna sequences coding therefor, antibodies to the proteins
WO2000018803A3 (en) Antibodies to mammalian langerhans cell antigen and their uses
CA2199403A1 (en) Novel PKA-Binding Proteins and Uses Thereof
WO2000077207A3 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2270875

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 522900

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997949469

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997949469

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997949469

Country of ref document: EP